Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution

Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution

Abstract Background Most patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) will relapse if treatment is withdrawn, but various trials have recently demonstrated that a significant proportion of patients who achieved a stable and deep molecular response (DMR)...

Full description

Bibliographic Details
Main Authors: Nuno Cerveira, Bruno Loureiro, Susana Bizarro, Cecília Correia, Lurdes Torres, Susana Lisboa, Joana Vieira, Rui Santos, Dulcineia Pereira, Cláudia Moreira, Sérgio Chacim, Nélson Domingues, Ana Espírito-Santo, Isabel Oliveira, Ilídia Moreira, Luísa Viterbo, Ângelo Martins, Manuel R. Teixeira, José M. Mariz
Format: Article
Language:English
Published: BMC 2018-12-01
Series:BMC Cancer
Subjects:
Chronic myeloid leukemia
TKI discontinuation
TKI therapy duration
Sustained deep molecular response
Unsustained deep molecular response
Online Access:http://link.springer.com/article/10.1186/s12885-018-5167-y

Internet

http://link.springer.com/article/10.1186/s12885-018-5167-y

Similar Items